CD8A and neoplasm: These cells have a unique capability to prime CD8 T cells against MHC class I-restricted tumor antigens and have been shown to be essential for the effect of ICI in some tumor models.30 31 To assess the presentation of tumor antigen on the cell surface of cDC1s, we used a fluorescent antibody that recognizes the OVA SIINFEKL peptide docked in MHC-I.